Pharma Q2fy23 Preview
The Pharma universe under our coverage could report aggregate Revenue/EBITDA/PAT growth of 5.6%/-4.8%/-2.2% YoY. Currency (Rs) has depreciated by 5.0%
148 Views
Aarti Drugs: Price Hike and New Capacity to Aid in Growth
We believe the company’s profitability might be hit due to the above factors, prompting us to recommend a HOLD rating on the stock with TP Rs...
231 Views
Aarti Drugs: Growth Led by Price Hikes and New Capacity Addition
Aarti Drugs reported revenue growth of 19.7% YoY which stood above our expectations. The API segment grew by 22% while the Speciality Chemical...
165 Views
Aarti Drugs: Low Demand, High RM Prices Impact Profitability; Capex to Drive Growth
We expect revenue and PAT CAGR of 13.3% and 12.3% respectively over the period FY21-FY23E and recommend BUY with TP of Rs 760.
195 Views
India Small Caps: Position for Outperformance Vs Large & Mid Caps
Late Friday evening, the Securities and Exchange Board of Indian
578 Views